<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763516</url>
  </required_header>
  <id_info>
    <org_study_id>UFPTI 0704-PC02</org_study_id>
    <nct_id>NCT00763516</nct_id>
  </id_info>
  <brief_title>Proton Radiation for Resectable Carcinoma of the Pancreas</brief_title>
  <acronym>PC02</acronym>
  <official_title>A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, proton radiation
      combined with chemotherapy and surgery has on you and your pancreatic cancer. This study will
      look at the side effects from the treatment and the quality of your life in relation to pain.
      It will also look at how the tumor responds to the combination of treatment with radiation,
      chemotherapy and surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy capecitabine on radiation days

      Proton radiation over 6 weeks

      Surgery 6 weeks after radiation completion

      Adjuvant Chemotherapy starting 2-8 weeks after surgery with Gemzar
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 17, 2017</completion_date>
  <primary_completion_date type="Actual">August 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of grade 3+ bowel perforation, grade 3+ bleeding and grade 4+ nonhematologic acute adverse events (occuring within 90 days of treatment start)</measure>
    <time_frame>1 year following the completion of radiation therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and analyze tumor control outcomes</measure>
    <time_frame>1 year following the completion of radiation therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Proton radiation and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiation
Capecitabine chemotherapy on radiation days
Surgery
Gemcitabine chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation and chemotherapy</intervention_name>
    <description>Neoadjuvant Chemotherapy Capecitabine (Xeloda速) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only
Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks
Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation
Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar速) 1,000 mg/m2 IV total of 18 doses</description>
    <arm_group_label>Proton radiation and chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed adenocarcinoma of the pancreas.

          -  Patients must have marginally resectable disease.

          -  Patients with biliary obstruction must have adequate drainage prior to starting
             chemoradiation.

        Exclusion Criteria:

          -  Evidence of distant metastasis including peritoneal seeding and/or ascites.

          -  Previous irradiation to the abdomen that would compromise the ability to deliver the
             prescribed treatment.

          -  Prior surgical resection.

          -  Gastroduodenal obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romaine C Nichols, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Proton Therapy Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.floridaproton.org/contact/contact.html</url>
    <description>Contact the University of Florida Proton Therapy Institute</description>
  </link>
  <reference>
    <citation>Saif MW. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP. 2006 Jul 10;7(4):337-48.</citation>
    <PMID>16832131</PMID>
  </reference>
  <reference>
    <citation>Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995 Jan;82(1):111-5.</citation>
    <PMID>7881926</PMID>
  </reference>
  <reference>
    <citation>Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4.</citation>
    <PMID>10615932</PMID>
  </reference>
  <reference>
    <citation>Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987 Jun 15;59(12):2006-10.</citation>
    <PMID>3567862</PMID>
  </reference>
  <reference>
    <citation>Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, B端chler MW; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10. Erratum in: N Engl J Med. 2004 Aug 12;351(7):726.</citation>
    <PMID>15028824</PMID>
  </reference>
  <reference>
    <citation>Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997 Mar;15(3):928-37. Review.</citation>
    <PMID>9060530</PMID>
  </reference>
  <reference>
    <citation>Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, B端chler MW; European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001 Dec;234(6):758-68.</citation>
    <PMID>11729382</PMID>
  </reference>
  <reference>
    <citation>Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79.</citation>
    <PMID>11307091</PMID>
  </reference>
  <reference>
    <citation>Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, Hohenberger W. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer. 2007 Mar 6;7:41.</citation>
    <PMID>17338829</PMID>
  </reference>
  <reference>
    <citation>Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg. 2004 Jun;187(6):736-40.</citation>
    <PMID>15191867</PMID>
  </reference>
  <reference>
    <citation>Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34(2-3):121-8.</citation>
    <PMID>15361645</PMID>
  </reference>
  <reference>
    <citation>Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001 Mar-Apr;5(2):121-30.</citation>
    <PMID>11331473</PMID>
  </reference>
  <reference>
    <citation>White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005 Mar;12(3):214-21. Epub 2005 Mar 3.</citation>
    <PMID>15827813</PMID>
  </reference>
  <reference>
    <citation>Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001 Mar;8(2):123-32.</citation>
    <PMID>11258776</PMID>
  </reference>
  <reference>
    <citation>Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998 Sep;16(9):2977-85.</citation>
    <PMID>9738566</PMID>
  </reference>
  <reference>
    <citation>Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.</citation>
    <PMID>11304782</PMID>
  </reference>
  <reference>
    <citation>Dunst J, Reese T, Sutter T, Z端hlke H, Hinke A, K旦lling-Schlebusch K, Frings S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002 Oct 1;20(19):3983-91.</citation>
    <PMID>12351595</PMID>
  </reference>
  <reference>
    <citation>Bussels B, Goethals L, Feron M, Bielen D, Dymarkowski S, Suetens P, Haustermans K. Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol. 2003 Jul;68(1):69-74.</citation>
    <PMID>12885454</PMID>
  </reference>
  <reference>
    <citation>Eccles C, Brock KK, Bissonnette JP, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):751-9.</citation>
    <PMID>16458774</PMID>
  </reference>
  <reference>
    <citation>Korreman SS, Pedersen AN, N淡ttrup TJ, Specht L, Nystr旦m H. Breathing adapted radiotherapy for breast cancer: comparison of free breathing gating with the breath-hold technique. Radiother Oncol. 2005 Sep;76(3):311-8.</citation>
    <PMID>16153728</PMID>
  </reference>
  <reference>
    <citation>Sugahara S, Tokuuye K, Okumura T, Nakahara A, Saida Y, Kagei K, Ohara K, Hata M, Igaki H, Akine Y. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):76-84.</citation>
    <PMID>15629597</PMID>
  </reference>
  <reference>
    <citation>Gierga DP, Chen GT, Kung JH, Betke M, Lombardi J, Willett CG. Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1584-95.</citation>
    <PMID>15050340</PMID>
  </reference>
  <reference>
    <citation>Wong JW, Sharpe MB, Jaffray DA, Kini VR, Robertson JM, Stromberg JS, Martinez AA. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):911-9.</citation>
    <PMID>10386650</PMID>
  </reference>
  <reference>
    <citation>Singh AK, Tierney RM, Low DA, Parikh PJ, Myerson RJ, Deasy JO, Wu CS, Pereira GC, Wahab SH, Mutic S, Grigsby PW, Hope AJ. A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: implications for radiation dose escalation in carcinoma of the pancreas. Radiat Oncol. 2006 Sep 4;1:33.</citation>
    <PMID>16952315</PMID>
  </reference>
  <reference>
    <citation>Blackall JM, Ahmad S, Miquel ME, McClelland JR, Landau DB, Hawkes DJ. MRI-based measurements of respiratory motion variability and assessment of imaging strategies for radiotherapy planning. Phys Med Biol. 2006 Sep 7;51(17):4147-69. Epub 2006 Aug 8.</citation>
    <PMID>16912374</PMID>
  </reference>
  <reference>
    <citation>Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer. 1987 Sep 1;60(5):1151-8.</citation>
    <PMID>3300951</PMID>
  </reference>
  <reference>
    <citation>Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug;13(8):1035-46. Epub 2006 Jul 24. Review.</citation>
    <PMID>16865597</PMID>
  </reference>
  <reference>
    <citation>Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9.</citation>
    <PMID>15145162</PMID>
  </reference>
  <reference>
    <citation>Hsiung-Stripp DC, McDonough J, Masters HM, Levin WP, Hahn SM, Jones HA, Metz JM. Comparative treatment planning between proton and X-ray therapy in pancreatic cancer. Med Dosim. 2001 Fall;26(3):255-9.</citation>
    <PMID>11704461</PMID>
  </reference>
  <reference>
    <citation>Crane unpublished data presented at ASCO GI, 2006-Abstract # 106; Das, P., et al.).</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Proton radiation</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Resectable</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

